How to give a subcutaneous injection of a blood thinner using a prefilled syringe

This information explains how to prepare and give a subcutaneous injection (shot) of a blood thinner using a prefilled syringe. Throughout this material, we use the words “you,” “your,” and “yourself” to refer to you or your child.

You need to give yourself injections (shots) of medication to thin your blood. You will receive syringes already filled with medication from your pharmacy. You will inject the medicine into the fat layer under the skin using a small, thin needle.

You may receive a pre-filled syringe with a needle already attached to it, or you may need to thread it yourself. If you received a syringe without a needle, attach it by following the instructions in the “Preparing the Injection” section.

You will practice preparing and giving yourself an injection with your nurse. Refer to this material at home the first few times you inject yourself.

to come back to the beginning

Preparing the injection

Prepare a clean surface on which you will place everything you need, such as a kitchen table. Do not use surfaces in the bathroom. Line the surface with clean, dry paper towels.
Check the name and dose of the medication on the prefilled syringe.
Prepare everything you need:
a pre-filled syringe with a needle attached;
2 alcohol wipes;
a sharps disposal container, such as an empty plastic bleach or detergent bottle with a cap and label “Household sharps - do not recycle”;
gauze or cotton swab 5 x 5 cm;
bandage.
Wash your hands:
If you are using an alcohol-based hand sanitizer, be sure to apply it all over your hands, including the skin between your fingers, and rub your hands until it is completely dry.
Check if the syringe has a needle. If it is not there, follow the steps below to attach the needle to the syringe.

Putting on the needle:

open the package with a new needle, but do not take it out yet; place the open package on a work surface;
remove the black cap from the end of the syringe; Make sure that after removing the cap, nothing, including your fingers, touches the end of the syringe; if anything touches the end of the syringe, it should be thrown away;
remove the needle from the package; Do not remove the protective cap from the needle. Be careful not to let anything, including your fingers, touch the needle. If anything touches the needle, it should be thrown into a sharps container.
Place the needle on the base of the syringe and turn it clockwise (to the right).

Figure 1. Injection site selection

to come back to the beginning

VTE - venous thromboembolism

INR - international normalized ratio

LMWH - low molecular weight heparin

TEO - thromboembolic complications

AF - atrial fibrillation

In the United States, more than 2.5 million patients are chronically treated with anticoagulants due to the development of venous thromboembolism (VTE), implantation of mechanical valve prostheses in the heart, or atrial fibrillation (AF) [1]. Every year, in approximately 10% of such patients, the use of anticoagulant therapy is temporarily stopped due to invasive interventions. To select an acceptable management strategy for such patients, it is necessary to assess the risk of thromboembolism and severe bleeding during the intervention period. A temporary change in anticoagulant therapy during the intervention period is usually referred to in the English literature as “bridging therapy.” This change in therapy usually involves the use of parenteral short-acting anticoagulants while warfarin is temporarily discontinued. Below is a systematic approach to choosing tactics for using anticoagulant therapy during invasive interventions.

There is no generally accepted tactics for the use of anticoagulant therapy during the period of invasive intervention in patients taking warfarin for a long time. However, a systematic approach to choosing such tactics may be useful. If it is necessary to perform an urgent or emergency intervention, there is usually no time to transfer the patient to therapy with another anticoagulant for the duration of the intervention. The effect of warfarin in such cases can be reversed by administration of fresh frozen plasma and parenteral administration of vitamin K.

If the proposed intervention is considered planned, it is necessary to answer the question about the need to stop taking the anticoagulant during its implementation. It should be noted that many interventions can be performed safely without interruption of anticoagulant use. These include, for example, tooth extraction, bone marrow biopsy, endoscopy (including mucosal biopsy), cataract surgery, pacemaker installation, venography, dermatological operations, and aspiration of fluid from the joint cavity. Before performing such interventions, the intensity of warfarin therapy is usually reduced to achieve a lower therapeutic range of international normalized ratio (INR) values.

If anticoagulants must be discontinued, the need for a temporary switch to parenteral anticoagulant administration during the intervention should be assessed. Such a transition is not required in the following patients: 1) with a low risk of developing thromboembolic complications (TEC), including patients with AF and a CHADS2 score of 2 points or less in the absence of previous thromboembolism and blood clots in the cavities of the heart; 2) in the presence of a bicuspid mechanical prosthesis implanted in the aortic position in the case of maintaining sinus rhythm and in the absence of previously suffered thromboembolism; 3) who had VTE more than 3 months ago in the absence of active forms of cancer. In such patients, warfarin can be discontinued 4-5 days before the intended intervention. On the morning of the intervention, confirmation should be obtained that the INR level is within the required range. Warfarin administration in such cases is resumed on the day of the intervention, as soon as hemostasis is achieved and the patient can take the drug. Postoperative patient characteristics that should be considered when deciding whether to restart warfarin include the need for additional intervention and the expected timing of its implementation; the use of drugs that interact with warfarin, including antibiotics; limited food intake. The need for more frequent INR determinations should be taken into account. In addition, appropriate mechanical and pharmacological methods for VTE prophylaxis should be used until anticoagulant therapy has been fully resumed.

The ongoing Bridge Trial, funded by the National Institutes of Health, will evaluate the safety and effectiveness of temporarily switching patients with AF to low molecular weight heparin (LMWH) during invasive procedures [2]. This study is expected to enroll 3626 patients and will end in 2014 or 2015. It is believed that the results of this study will answer the question of whether temporary switching to LMWH is required during the period of invasive surgery in patients with AF and AF. CHADS2 score 3 or 4, with no history of stroke or thromboembolism.

In cases where the risk of thromboembolism is assessed as moderate or high, a temporary transfer of the patient to parenteral LMWH is considered mandatory. According to experts, in patients observed on an outpatient basis, in such cases, subcutaneous administration of LMWH is preferable whenever possible due to the convenience of dosing, safety and low cost of such therapy [3, 4]. In case of severe renal impairment (decrease in creatinine clearance to 15-30 ml/min, which corresponds to stage IV of chronic kidney disease), the dose of LMWH should be reduced; in addition, monitoring of anti-Xa activity is necessary during therapy [5]. In patients with stage V chronic kidney disease, intravenous infusions of unfractionated heparin should be used for such purposes. After discontinuation of warfarin, the daily dose of LMWH is started as soon as the INR falls below the therapeutic range [6–8]. In patients at high risk of developing TEC who have mechanical valve prostheses implanted, LMWH is administered 2 times a day in accordance with clinical recommendations [9, 10]. In all other cases, LMWH is administered once. In order to avoid the residual effect of LMWH on the day of surgery, in the morning of the day of surgery, but before the start of its implementation, LMWH is administered at a dose corresponding to 50% of the calculated daily dose [11]. After surgery, warfarin should be restarted with caution at the earliest opportunity. Heparin can be administered no earlier than 48 hours after completion of the operation in order to reduce the risk of severe bleeding, and the possibility of using small doses of heparin should be considered [6-8, 12]. After surgery where there is a high risk of severe bleeding, when heparin is reintroduced, its use should initially be limited to prophylactic doses, if it can be used at all. Intravenous administration of unfractionated heparin without bolus administration has the advantages of rapid elimination of the drug and the possibility of neutralizing its effect due to the administration of protamine; in such cases, this approach to heparin therapy may be preferable. In patients with VTE after surgery, prophylactic use of LMWH is acceptable. Moreover, warfarin and heparin should be used simultaneously for at least 5 days or until the INR corresponds to the therapeutic range, depending. Depending on the indications and the nature of the invasive procedure, aspirin may be discontinued 1 week before the intended intervention.

In patients with a history of VTE, there is a general tendency to implant a filter into the inferior vena cava as a component of VTE prophylaxis during an invasive procedure [8]. In patients with acute or subacute VTE, elective surgery should be postponed until the period of anticoagulant use has reached 3 months. Implantation of a filter into the inferior vena cava can only be recommended for patients who require urgent surgical intervention within a month after the diagnosis of VTE. It is preferable to implant removable filters, which should be removed as soon as the need for their use ceases.

If there is a history of thrombocytopenia due to the use of heparin, the administration of any heparin preparations should be avoided. Short-acting direct thrombin inhibitors such as argatroban, lepirudin or bivalirudin are used as alternative therapy in such cases. The use of desirudin is particularly attractive because it can be administered subcutaneously, allowing the patient to be monitored on an outpatient basis. In patients with thrombocytopenia caused by the use of heparin, fondaparinux is often used, but its use during invasive interventions is problematic due to the long half-life, which reaches 17-21 hours.

In general, the risk of bleeding during interventions is 2 times higher than the risk of thrombosis. Relatively recently, the BleedMAP scale was developed to assess the risk of bleeding during an invasive procedure [12]. When assessed using this scale, a score of 1 corresponds to each of the following risk factors: a history of bleeding (Bleed), a mechanical valve implanted in the heart (M), active cancer (A), and a low blood platelet count (P, for platelet; platelet count 150,000/µl or less). Although the validity of such a scale has not yet been assessed in a prospective study, its use allows the risk of bleeding to be established based on clinical data. It should also be noted that this is currently the only scale available to assess the risk of bleeding when using anticoagulants during an invasive procedure.

The tactics of anticoagulant therapy in patients taking “new” anticoagulants are separately considered. Dabigatran etexilate (Pradaxa) is an oral direct thrombin inhibitor that has been approved by the US Food and Drug Administration for use in the prevention of stroke in patients with nonvalvular AF [13]. The period to achieve the maximum effect after taking dabigatran is about 1 hour, the half-life of the drug reaches approximately 15 hours, and it is eliminated predominantly (about 80%) through the kidneys. Rivaroxaban (Xarelto) is an oral direct factor Xa inhibitor that has also been approved by the US Food and Drug Administration for use in the prevention of stroke in patients with non-valvular AF [14], as well as for the prevention of VTE after prosthetic replacement. large joints. Rivaroxaban is metabolized in the liver (33%) and excreted through the kidneys (66%). The half-life ranges from 7 to 11 hours.

According to experts, the management of patients taking dabigatran or rivaroxaban is more conservative than the recommendations of the manufacturers of these anticoagulants, which is due to several reasons [15]. Firstly, the incidence of thromboembolism during invasive interventions is low (1%). Secondly, after taking both dabigatran and rivaroxaban, their onset of action is rapid (within 1-2 hours), and the half-life of both drugs is quite long. Third, there is no antidote for dabigatran. Data have been obtained that the use of prothrombin complex concentrate leads to neutralization of the effect of rivaroxaban in healthy volunteers [16].

The first step is to evaluate the risk of bleeding associated with a particular type of surgery and a particular type of anesthesia (eg, spinal). In any case, the operating surgeon and anesthesiologist must be aware that the patient is taking a “new” anticoagulant. It is also necessary to re-determine creatinine clearance to ensure that the dose used is correct. If the intervention is urgent or urgent, an increased risk of bleeding should be expected and this risk should be weighed against the possible consequences of delaying the intervention. Mechanical interventions to stop bleeding include suturing the vessel, clipping it, applying pressure to the bleeding area, cooling, cauterization, and topical thrombin. In case of massive bleeding, the decision to use hemostatic agents such as prothrombin complex concentrate, Factor Eight Inhibitor Bypass Activity complex or recombinant factor VIIa should be made taking into account the risk of thrombotic complications [15, 16].

During planned interventions in patients taking “new” anticoagulants, creatinine clearance should first be assessed. In patients with a creatinine clearance of 50 ml/min or more before intervention, it is recommended to discontinue the anticoagulant for a period corresponding to 4-5 half-lives of the drug. In patients with creatinine clearance less than 50 ml/min, the duration of the period of discontinuation of the drug should be increased by another 2 days. Before surgery with a high risk of bleeding, a normal activated partial thromboplastin time or thrombin time indicates sufficient elimination of dabigatran. There are currently no laboratory tests available to confirm complete elimination of rivaroxaban. In most cases, transferring a patient to heparin during an invasive procedure is usually not indicated. After surgery, it is necessary to re-ensure sufficient kidney function. Resumption of dabigatran and roveroxaban should be delayed for 48 hours, and their use is possible only if complete control of bleeding is confirmed. It should be noted that within 1-2 hours after resuming dabigatran and rivaroxaban, the patient will achieve full anticoagulant effect. If the patient has a high risk of bleeding or additional interventions are expected to be performed in the near future, according to experts, it is advisable to use standard anticoagulant therapy, the effect of which can be eliminated if necessary.

Currently, researchers have provided data on 4591 patients with non-valvular AF who, during the study, were randomly assigned to the dabigatran group (110 or 150 mg 2 times a day) or the warfarin group [17]. Dabigatran and warfarin were discontinued on average 2 and 4 days before the intervention, respectively. The time of resumption of anticoagulants after the intervention was determined by the attending physician. The incidence of bleeding within 30 days was not statistically significantly different between groups (in the dabigatran 110 mg twice daily group, in the dabigatran 150 mg twice daily group, and in the warfarin group, the incidence reached 3.8, 5.1 and 46% respectively), but overall was 2 times higher than previously reported for warfarin therapy. The incidence of TEC was low, approximately 1% in each group. Despite the importance of such data, the disadvantages of this article should be noted: the secondary nature of the analysis, changes in treatment tactics during the study, the lack of a standardized approach to anticoagulant therapy (especially when deciding on its resumption after the intervention) and the lack of a standard definition of “major” intervention. In fact, less than 17% of the interventions performed in the study could be classified as “major” from the perspective of practitioners. According to experts, until additional data is obtained on the incidence of bleeding in patients who have undergone “major” interventions, the approach to determining the tactics of using anticoagulants during the period of interventions should remain conservative.

Moreover, in their practice, experts avoid the use of dabigatran and rivaroxaban in cases of catheter installation in the spinal cord canal and/or epidurally or in the deep plexus due to the increased risk of hematoma development. After removal of catheters installed in the spinal cord canal or deep plexus and/or in the peripheral parts of the nervous system, resumption of dabigatran and rivaroxaban should be delayed for 24 hours.

It should also be noted that patients with active forms of cancer who take anticoagulants for a long time have a predisposition to the development of both thrombosis and bleeding. Anticoagulant therapy in such cases is complicated by the use of chemotherapy, the installation of central venous catheters, the presence of cytopenias, the use of hormonal agents, drug interactions, as well as variability in diet and diet. The results of a recent study [18] indicate that during the period of invasive procedures in a subgroup of patients with active forms of cancer (n = 493) compared with a subgroup of patients who did not have cancer (n = 1589), the incidence of VTE and severe bleeding was statistically significantly higher: VTE developed in 1.2 and 0.2% of patients, respectively, and severe bleeding - in 3.4 and 1.7% of patients, respectively. This difference was mainly driven by data from patients who used anticoagulants for cancer-related VTE. In such patients, during the period of invasive interventions, experts recommend a more frequent transfer to LMWH therapy in sufficient doses. The last dose of LMWH administered 24 hours before the intervention should be 50% of the total daily dose of the drug. After intervention, the use of LMWH should be limited to prophylactic doses until complete control of bleeding is confirmed. The use of therapeutic doses of LMWH should be avoided for 48 hours after the procedure to prevent severe bleeding. Many patients with cancer-related VTE are treated with long-term LMWH.

Carrying out the injection

Make sure the correct amount of medication is filled into the syringe. Don't worry if you notice small air bubbles in the syringe.
Select the injection site from those shown in Figure 1. Remember where you gave the previous injection and choose a different site each time. Change places according to your schedule. Do not inject in areas less than 2 inches (5 centimeters) from scars, cuts, or wounds.
Remove or tuck any clothing covering the injection site.
Wipe the area where you will be injecting with an alcohol wipe. Let it air dry. Do not fan or blow on the area.
Take the syringe with your dominant hand (the hand you write with). With your other hand, remove the protective cap from the needle. Try not to let anything, not even your fingers, touch the needle. If anything touches the needle, it should be thrown into a sharps container. See “What to do if something touches the needle” for instructions.
Hold the syringe as if it were a dart (by holding it between your index and middle fingers on one side and your thumb on the other).
Using your nondominant hand (the hand you're not writing with), pull back 1 to 2 inches (2.5 to 5 centimeters) of skin near the injection site, pinching it between your thumb and index finger. Hold the syringe in your other hand.
In one quick motion, insert the needle into the skin at a 90-degree angle (right angle) (see Figures 2 and 3).
Figure 2. Injection administration
Figure 3. Needle insertion

to come back to the beginning

Heparin therapy in the acute period of myocardial infarction

A.N.YAKOVLEV , Doctor of Medical Sciences, Professor, Federal State Institution “Federal Center of Heart, Blood and Endocrinology named after V.A. Almazov Rosmedtekhnologii”, St. Petersburg

The development of acute thrombosis of the coronary artery is the leading pathogenetic mechanism of destabilization of the course of coronary heart disease. Drug interventions related to the effect on the blood coagulation system play a key role in the treatment of patients in the acute period of myocardial infarction after reperfusion therapy (thrombolysis or primary coronary angioplasty), if the latter can be performed taking into account the timing of the disease and possible contraindications. The maximum therapeutic effect can be achieved by simultaneous administration of drugs that act on different parts of hemostasis. Correct prescription of anticoagulants and antiplatelet agents can reduce the risk associated with both the threat of relapse of the disease with expansion of the area of myocardial damage, and the risk of bleeding.

In practical medicine, a rather narrow range of drugs is used, the effectiveness of which has been proven in large multicenter randomized clinical trials. Thus, unfractionated heparin, low molecular weight heparins, fondaparinux are used as anticoagulants, and acetylsalicylic acid and clopidogrel are used as antiplatelet drugs. Unfractionated heparin

The official heparin solution contains a mixture of sulfated polysaccharides with a molecular weight of 2000 to 30,000 Da. About a third of the drug molecules consist of 18 or more polysaccharide residues and, in combination with antithrombin III, can significantly reduce the activity of thrombin (factor IIa), as well as Xa, IXa and other coagulation factors. Inhibition of thrombin is accompanied by a decrease in coagulation, which can be assessed by determining the activated partial thromboplastin time (aPTT). The antithrombotic effect is mainly due to inhibition of prothrombinase (factor Xa). Short chain heparin has a low molecular weight and primarily affects factor Xa. The bioavailability of heparin is low and is influenced by many factors - interaction with plasma proteins, uptake by endothelial cells and macrophages, platelet activity. Also important is the plasma level of antithrombin III, with which heparin forms an active complex.

In Russia, unfractionated heparin is used in the form of a sodium salt solution (Heparin Sodium) containing 5000 IU of heparin per 1 ml. With a single intravenous administration, the effect of the drug occurs immediately and lasts up to 3 hours; The half-life from plasma is 30-60 minutes. The most stable and controlled hypocoagulation effect is observed with prolonged intravenous infusion using a syringe or pump dispenser, therefore this method of administration is standard when treating with unfractionated heparin.

In myocardial infarction, anticoagulant therapy with heparin should be started as soon as possible after the onset of symptoms.

The relationship between the dose of heparin and its anticoagulation effect is nonlinear. The severity and duration of the effect increases disproportionately with increasing dose. Thus, with an intravenous bolus of 25 IU/kg, the half-life of heparin is 30 minutes, with a bolus of 100 IU/kg - 60 minutes, with 400 IU/kg - 150 minutes. To objectively assess the anticoagulant effect of heparin and get an idea of the state of the internal pathway of plasma hemostasis, it is possible to determine the activated partial thromboplastin time (aPTT), which reflects the initial stage of coagulation - the formation of thromboplastin. When treating with heparin, it is necessary to determine the aPTT, since it is this indicator that allows you to individually select the dosage regimen and monitor the effectiveness of therapy.

The development of bleeding is the most likely and dangerous complication of heparin therapy. Most often, the source of blood loss is erosion and ulcerative defects localized in the upper parts of the gastrointestinal tract. It should be noted that the development of posthemorrhagic anemia in patients with myocardial infarction is an independent unfavorable prognostic factor. A detailed history collection, including information on previous anticoagulant therapy, identification of symptoms of hemorrhagic diathesis, determination of the platelet count and initial aPTT allows assessing the risk of developing hemorrhagic complications.

When treating with heparin, it is necessary to determine the aPTT, since it is this indicator that allows you to individually select a dosage regimen and monitor the effectiveness of therapy

Serious complications are also the development of thrombocytopenia followed by heparin-induced thrombosis, osteoporosis, and antithrombin III deficiency.

A number of multicenter studies (ATACS, RISC, SESAIR and others) have confirmed the effectiveness of heparin and combination therapy with heparin and aspirin in acute myocardial infarction (AMI). In the prethrombolytic era, heparin administration led to a reduction in deaths (by 17%), recurrent infarctions (by 22%), as well as a decrease in the incidence of strokes and episodes of pulmonary embolism. At the same time, the number of non-cerebral bleedings increased.

The effectiveness of heparin in AMI in combination with thrombolytic therapy was assessed in the GUSTO study. In the group of patients receiving continuous intravenous infusion of heparin, the patency of the coronary artery supplying the infarction area was significantly higher (84 vs. 71%, p<0.05), and the 5-year survival rate was 1% higher compared to the group of patients receiving heparin by subcutaneous injection. In accordance with current recommendations for the treatment of AMI, unfractionated heparin can only be prescribed as a continuous intravenous infusion.

In myocardial infarction (MI), anticoagulant therapy with heparin should be started as soon as possible after the onset of symptoms. For non-ST segment elevation MI, treatment with unfractionated heparin should be continued for at least 48 hours. For ST-segment elevation MI, heparin treatment is considered as part of a reperfusion strategy. In the case of thrombolytic therapy, the administration of heparin should begin simultaneously with it and continue for at least 24-48 hours. When performing primary coronary angioplasty, heparin is administered before and during the procedure. If the intervention is successful, heparin therapy can be discontinued.

For ST-elevation MI without reperfusion therapy, treatment tactics with unfractionated heparin are similar to those for thrombolytic therapy. Thrombolytic therapy with streptokinase is the only clinical situation in which current recommendations allow the use of fixed doses and subcutaneous administration of unfractionated heparin. In this case, it is possible to administer a bolus of 5000 IU of heparin followed by an infusion of 1000 IU/hour in patients weighing over 80 kg and 800 IU/hour in patients weighing less than 80 kg. Only in this situation, instead of infusion, subcutaneous administration of heparin at a dose of 12,500 IU twice a day is permissible.

The current standard for prescribing therapy with unfractionated heparin is to individually calculate the dose depending on body weight, taking into account the clinical situation and concomitant therapy. Rules for calculating the dose of heparin are presented in Table 1.

Therapy is monitored by re-evaluating the APTT. Target APTT values are considered to be within 50–75 seconds or 1.5–2.5 times higher than the upper limit of normal established for a given laboratory. During the first day after the start of heparin therapy, it is advisable to determine the aPTT at 3, 6, 12 hours from the start of the infusion and then depending on its values (Table 2). After changing the infusion rate, the APTT is re-monitored after 6 hours. If APTT values exceed 130 seconds, it is recommended to take a break in the infusion for 90 minutes and conduct additional monitoring of the APTT at the end of the infusion break. If the aPTT is within the target range for two consecutive measurements with an interval of at least 6 hours against the background of a constant rate of heparin infusion, in the future it is permissible to monitor the aPTT once a day if the rate of heparin administration remains the same. In case of hemorrhagic complications, APTT must be determined immediately.

In some cases, in particular with a deficiency of coagulation factors, antiphospholipid syndrome, against the background of thrombolytic therapy, when taking indirect anticoagulants, the specificity of the APTT test can be significantly reduced.

In rare cases, high doses of heparin (more than 35,000 IU per day) are required to achieve target aPTT values, indicating heparin resistance. To confirm the phenomenon, it is recommended to determine the activity of the factor Xa inhibitor. Low molecular weight heparins

Low molecular weight heparins are preparations of mucopolysaccharides with a molecular weight of 4000–7000 Da. Low molecular weight heparins, unlike unfractionated heparins, have an antithrombotic effect by inhibiting factor Xa and without having a significant effect on thrombin activity. Heparins, which have very short polysaccharide chains and a very low molecular weight, do not have an aptithrombotic effect. With chain lengths ranging from 8 to 18 polysaccharide units, the drugs primarily inhibit factor Xa and exhibit antithrombotic activity with a minimal risk of bleeding. The bioavailability of low molecular weight heparins reaches almost 100%, while the half-life is 2-4 times higher than that of unfractionated heparin. In general, low-molecular-weight heparins have a more predictable, long-lasting, and selective effect and can be administered by subcutaneous injection once or twice daily. Therapy with low molecular weight heparins does not require monitoring of laboratory parameters of blood coagulation.

The main pharmacological characteristics of low molecular weight heparins are presented in Table 3.

Adverse effects when treated with low molecular weight heparins are similar to those when using unfractionated heparin. Moreover, according to a meta-analysis that combined data on 4669 patients, in the group of patients receiving low molecular weight heparins, the risk of major bleeding was 52% lower. The metabolism of low molecular weight heparins is carried out with the participation of the kidneys, therefore the use of drugs of this group in patients with a decrease in creatinine clearance of less than 30 ml/hour is contraindicated.

Therapy with low molecular weight heparins does not require monitoring of laboratory parameters of blood clotting

The most studied drug from the group of low molecular weight heparins for use in patients with AMI is enoxaparin, registered for use both in acute coronary syndrome without ST-segment elevation and in AMI with ST elevation. According to the results of a meta-analysis of 6 large multicenter studies, including a total of about 22,000 patients with acute coronary syndrome, the advantages of enoxaparin therapy compared with unfractionated heparin were convincingly demonstrated, consisting in a significant reduction in the risk of death and non-fatal myocardial infarction.

In combination with thrombolytic therapy, the use of enoxaparin is preferable to unfractionated heparin. For patients under 75 years of age without renal impairment, bolus intravenous administration of enoxaparin at a dose of 30 mg is indicated, followed (after 15 minutes) by subcutaneous administration at a rate of 1 mg/kg every 12 hours. For patients over 75 years of age, bolus administration is not required. The duration of enoxaparin therapy should not exceed 8 days.

When performing primary endovascular intervention, an infusion of unfractionated heparin should be prescribed. In patients who have not received reperfusion therapy, enoxaparin can be used in accordance with the above regimen for patients who have received thrombolytic therapy.

Conclusion

Heparin therapy is an integral component in the treatment of patients with myocardial infarction. To achieve maximum effect, it is necessary to adequately select the drug, taking into account contraindications, assessing possible risks, carefully following dosing recommendations and conducting adequate laboratory monitoring.

Literature

1. Panchenko E.G., Dobrovolsky A.B. Possibilities for diagnosing hemostasis disorders and promising directions of antithrombotic therapy for coronary heart disease. // Cardiology. – 1996. – No. 5. – P. 4-9. 2. Cairns JA, Throux P, Lewis HD, Ezekowitz M, Meade TW Antithrombotic Agents in Coronary Artery Disease. In: Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001; 119:228S—252S. 3. Dinwoodey DL, Ansell JE Heparins, Low-Molecular-Weight Heparins, and Pentasaccharides: Use in the Older Patient. // Cardiol. Clin. – 2008/ – V. 26. P. 145–155. 4. Hirsh J., Bauer KA, Donati MB Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133; 141S—159S. 5. Kitchen S. Problems in laboratory monitoring of heparin dosage. // Br. J. Haematol. 2000. – V. 111. – P. 397–406. 6. MacMahon S., Collins R., Knight C. Reduction in major morbidity and mortality by heparin in acute myocardial infarction. // Circulation. – 1998. – V. 78(suppl II). –P. 98.-104. 7. Peterson JL, Mahaey KW, Hasselblad M. Ef?cacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndrome. // JAMA. – 2004. – V. 292. P. 89–96. 8. The Global Utilization of Streptokinase, and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. // N. Engl. J. Med. – 1993. V. 329 (10). – P. 673-82.

Tables and figures are in the attached file

What to do if something touches the needle

If you are using a syringe with a pre-attached needle, dispose of it in a sharps container. Start the procedure again with a new pre-filled syringe.

If you throw away a syringe with a pre-attached needle, you will need to get a new dose of the medicine. Call your doctor for a prescription.
If you put the needle on the syringe yourself, follow the steps below to replace the needle.

Remove the old needle from the syringe by turning the base of the needle counterclockwise (to the left, Figure 4).

Figure 4. How to rotate the needle at the base

After you remove the needle, throw it into a sharps container. Make sure nothing touches the base of the syringe.
Remove the new capped needle from the package. Place the needle on the syringe by turning it clockwise (to the right).

to come back to the beginning

Storing medical needles

Use an empty plastic container with a screw cap, such as a detergent bottle. Choose a container that is thick enough that the needles will not pierce the sides.
Choose a container that is unbreakable.
Do not store medical needles in glass bottles, plastic drink bottles, milk bottles, aluminum cans, coffee cans, paper or plastic bags.

Clearly label the container “Household Medical Needles - Not for Recycling.” Keep it out of the reach of children and pets.

Place sharps in a container immediately after use.

Do not overfill the container. When the container is half full, replace it. Wrap the lid with strong adhesive tape to ensure the lid fits tightly and nothing leaks out.

Keep the container separate from recyclable waste.

to come back to the beginning